Literature DB >> 2806991

Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease?

G Crama-Bohbouth1, A S Pena, I Biemond, H W Verspaget, D Blok, J W Arndt, I T Weterman, E K Pauwels, C B Lamers.   

Abstract

We have investigated the correlation of 24 h and 48 h faecal Indium-111 excretion with each other and with several clinical activity indices for Crohn's disease (CD): Crohn's disease activity index (CDAI), activity index (AI), simple index (SI), Oxford score, and laboratory parameters, such as ESR, serum albumin, orosomucoid, C-reactive protein, alpha-l-antitrypsin (alpha 1-AT) faecal concentration, and alpha 1-AT clearance in 58 CD patients (37 with small bowel and 21 with colonic disease). A significant correlation was found between 24 and 48 h faecal Indium-111 excretion for small bowel (r = 0.708, p less than 0.0001) and colonic disease (r = 0.994, p less than 0.0001). The median faecal Indium-111 excretion for colonic involvement (4%; 0.15-50% median and range) was significantly (p less than 0.005) higher than that for small bowel disease (0.45%; 0.03-2.9%). No significant correlation was found between faecal Indium-111 excretion and any activity index in the patients with small bowel disease, while in the group of patients with colonic localisation only the AI showed a significant correlation (r = 0.593, p less than 0.02). Faecal Indium-111 excretion was significantly correlated with alpha 1-AT clearance (r = 0.712, p less than 0.0001) and faecal alpha 1-AT concentration (r = 0.750, p less than 0.0001) in small bowel and in colonic localisation (r = 0.530, p less than 0.02 and r = 0.444, p less than 0.05). Serum albumin was significantly correlated only in the group of patients with colonic disease (r = -0.593, p less than 0.05). The present study shows poor agreement between activity indices, serum parameters of activity and faecal Indium-111 excretion. As a good correlation was found with the alpha1-clearance, which reflects losses into the gut, these results may suggest that faecal Indium excretion does not only reflect activity of inflammation, but my relate to the extent of intestinal ulceration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2806991      PMCID: PMC1434263          DOI: 10.1136/gut.30.9.1236

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease.

Authors:  F T de Dombal; A Softley
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

2.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

3.  Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease.

Authors:  S H Saverymuttu; A M Peters; J P Lavender; M B Pepys; H J Hodgson; V S Chadwick
Journal:  Gastroenterology       Date:  1983-12       Impact factor: 22.682

4.  Specificity of indium-111 granulocyte scanning and fecal excretion measurement in inflammatory bowel disease--an autoradiographic study.

Authors:  A Keshavarzian; Y E Price; A M Peters; J P Lavender; N A Wright; H J Hodgson
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

5.  Indium-111 tagged leucocytes in the diagnosis of inflammatory bowel disease.

Authors:  A W Segal; J Ensell; J M Munro; M Sarner
Journal:  Lancet       Date:  1981-08-01       Impact factor: 79.321

6.  Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases.

Authors:  W Fischbach; W Becker; J Mössner; W Koch; C Reiners
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

7.  Value of indium-111 granulocyte scintigraphy in the assessment of Crohn's disease of the small intestine: prospective investigation.

Authors:  G E Crama-Bohbouth; J W Arndt; A S Peña; H W Verspaget; R T Tjon A Tham; I T Weterman; E K Pauwels; C B Lamers
Journal:  Digestion       Date:  1988       Impact factor: 3.216

8.  Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion.

Authors:  S H Saverymuttu; M Camilleri; H Rees; J P Lavender; H J Hodgson; V S Chadwick
Journal:  Gastroenterology       Date:  1986-05       Impact factor: 22.682

9.  Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI).

Authors:  W R Best; J M Becktel; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

  9 in total
  17 in total

1.  Structural heterogeneity of faecal alpha 1 antitrypsin shown by immunoblot analysis in patients with Crohn's disease.

Authors:  F Boege; W Fischbach
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

2.  Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis.

Authors:  Colm B Collins; Carol M Aherne; Stefan F Ehrentraut; Mark E Gerich; Eóin N McNamee; Martine C McManus; Matthew D P Lebsack; Paul Jedlicka; Tania Azam; Edwin F de Zoeten; Charles A Dinarello; Jesús Rivera-Nieves
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

3.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.

Authors:  F Costa; M G Mumolo; L Ceccarelli; M Bellini; M R Romano; C Sterpi; A Ricchiuti; S Marchi; M Bottai
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

4.  Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis.

Authors:  Sami Karoui; Sonia Laz; Meriem Serghini; Norsaf Bibani; Jalel Boubaker; Azza Filali
Journal:  Dig Dis Sci       Date:  2010-12-03       Impact factor: 3.199

5.  Comparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of X-ray-demonstrated lesions of Crohn's disease.

Authors:  C Brignola; C Belloli; P Iannone; G De Simone; C Corbelli; M Levorato; V Arienti; L Boriani; P Gionchetti; A Belluzzi
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

6.  Labelled leucocyte scintigraphy in inflammatory bowel disease: clinical applications.

Authors:  M H Giaffer
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

Review 7.  Enteral nutrition as primary therapy in Crohn's disease.

Authors:  F Fernández-Bañares; E Cabré; F González-Huix; M A Gassull
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

8.  A simple method for assessing intestinal inflammation in Crohn's disease.

Authors:  J Tibble; K Teahon; B Thjodleifsson; A Roseth; G Sigthorsson; S Bridger; R Foster; R Sherwood; M Fagerhol; I Bjarnason
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

9.  Calprotectin as a diagnostic tool for inflammatory bowel diseases.

Authors:  Marianthi Chatzikonstantinou; Panagiotis Konstantopoulos; Spyros Stergiopoulos; Konstantinos Kontzoglou; Christos Verikokos; Despina Perrea; Dimitris Dimitroulis
Journal:  Biomed Rep       Date:  2016-09-07

10.  Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial.

Authors:  F González-Huix; R de León; F Fernández-Bañares; M Esteve; E Cabré; D Acero; A Abad-Lacruz; M Figa; M Guilera; R Planas
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.